- $64.37m
- -$50.66m
- $63.26m
Brief: Fortress Biotech Enters Into $35 Mln Term Loan With Oaktree
Brief: Fortress Biotech Announces Pause In Payment Of Dividends On 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
Brief: Checkpoint Therapeutics Announces Biologics License Application Resubmission For Cosibelimab
Brief: Checkpoint Therapeutics Announces Alignment With FDA
Brief: Fortress Biotech Inc Files Prospectus Relates To Resale Of 2.4 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Brief: Mustang Bio Announces Favorable Efficacy And Safety Data From Phase 1/2 Clinical Trial Of MB-106 Car-T Therapy
Brief: Fortress Biotech Files For Mixed Shelf Of $50 Mln
Brief: Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
Fortress Biotech Inc reports results for the quarter ended in March - Earnings Summary
Brief: Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation
Fortress Biotech Inc expected to post a loss of $1.73 a share - Earnings Preview
Brief: Journey Medical Corporation Appoints Joseph Benesch As Chief Financial Officer
Brief: Avenue Therapeutics Announces Reverse Stock Split
Fortress Biotech Inc reports results for the quarter ended in December - Earnings Summary
Brief: Mustang Bio Expands Into Autoimmune Diseases With CAR T-Cell Therapy Platform
Fortress Biotech Inc expected to post a loss of $1.97 a share - Earnings Preview
Brief: Journey Medical Corporation Announces U.S. FDA Acceptance Of New Drug Application For DFD-29 For The Treatment Of Rosacea
Brief: Avenue Therapeutics Receives Positive Listing Determination from Nasdaq